Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Interventional Study of Neoadjuvant Durvalumab and Platinum-based Chemotherapy, Followed by Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab, in Borderline Resectable Stage III NSCLC (ACCESS)

NCT06998719 is registered in ClinicalTrials.gov with Bi Nan as lead sponsor.

NCT NCT06998719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06998719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Interventional Study of Neoadjuvant Durvalumab and Platinum-based Chemotherapy, Followed by Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab, in Borderline Resectable Stage III NSCLC (ACCESS)
Lead sponsor
Bi Nan
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 31, 2025
Completion date
December 31, 2027
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable carcinoma, non-small cell lung cancer stage iii